Compare AEI & NSPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AEI | NSPR |
|---|---|---|
| Founded | 2014 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Building operators | Medical/Dental Instruments |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 91.4M | 81.8M |
| IPO Year | N/A | N/A |
| Metric | AEI | NSPR |
|---|---|---|
| Price | $2.69 | $1.94 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $4.50 |
| AVG Volume (30 Days) | 37.1K | ★ 101.5K |
| Earning Date | 11-14-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $12,108,028.00 | $7,779,000.00 |
| Revenue This Year | N/A | $22.76 |
| Revenue Next Year | N/A | $75.45 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 14.04 |
| 52 Week Low | $0.70 | $1.59 |
| 52 Week High | $4.55 | $3.80 |
| Indicator | AEI | NSPR |
|---|---|---|
| Relative Strength Index (RSI) | 47.78 | 47.60 |
| Support Level | $2.68 | $1.74 |
| Resistance Level | $3.45 | $2.00 |
| Average True Range (ATR) | 0.35 | 0.12 |
| MACD | 0.02 | 0.01 |
| Stochastic Oscillator | 26.74 | 48.72 |
Alset Inc is a diversified holding company engaged through its subsidiaries in the development of EHome communities and other real estate, financial services, digital transformation technologies, biohealth activities, and consumer products with operations in the United States, Singapore, Hong Kong, Australia, and South Korea. The Company operates in four business segments: real estate, digital transformation technology, Biohealth, and other business activities, and it derives a majority of its revenue from the Real Estate segment.
InspireMD Inc is a United States based medical device company. It is focused on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of complex vascular and coronary disease. The products of the company are the CGuard carotid Embolic Prevention System (CGuard EPS) and the MGuard Prime Embolic Protection System (MGuard Prime EPS). It generates the majority of the revenue from the sales of CGuard EPS which combines MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. The group operates in Italy, Germany, Russia and other countries.